GSK's chemoattraction

In the Paleozoic era, small molecule drugs like methotrexate and steroids were just about the only game in town for serious autoimmune and inflammatory diseases. Then biologics became the hot thing because they represented a powerful new way to disrupt the important protein-protein interactions that play a key role in these diseases.

But with the success of the anti-TNFs in particular, it seems that every day there is a new approach seeking to provide better efficacy with fewer side effects. And with price becoming an ever more important issue, a return to small molecules has its appeal...